ArticleEuropean journal of nuclear medicine and molecular imaging2026
Stage migration in prostate cancer: the role of PSMA-PET in identifying oligometastatic disease.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOligometastatic disease (OMD) represents an intermediate disease state between localized and metastatic prostate cancer (PCa), where patients may still benefit from curative treatments. The prevalence of "de novo" metastatic disease detected by positron emission tomography (PET) with prostate specific membrane antigen (PSMA) in a real-world setting is still to be clarified. The primary aim was to compare the detection rates of OMD between PSMA-PET and conventional imaging (CI) in patients with intermediate- to high-risk PCa.
methodsThis multicenter retrospective study included patients with intermediate- to high-risk PCa who underwent both PSMA-PET and CI (contrast-enhanced CT and bone scintigraphy) within four months. The primary endpoint was to compare the detection rates of OMD (defined as ≤ 3 metastatic) between PSMA-PET and CI. The secondary endpoint was to assess treatment changes prompted by PSMA-PET findings.
resultsData of 497 patients were collected, and 255 patients met inclusion/exclusion criteria for the primary endpoint analysis, and all were considered for the secondary endpoint. OMD was identified using PSMA-PET in 11.4% of patients (29/255), significantly higher than the 6.7% rate (17/255) with CI (p = 0.040). In a retrospective multidisciplinary review, the intended clinical management changed in 36.5% (93/255) of cases, with major changes in 18.5% (e.g. a switch from curative therapy to systemic treatment) and minor changes in 18.0%. This reflects the intended treatment plan, not the treatment delivered. Limitations include the retrospective design, lack of central imaging review and absent patient follow-up. Also, the impact of PSMA-PET on survival has not been established.
conclusionsThis study shows that CI may underestimate de novo metastatic prostate cancer. Compared with CI, PSMA-PET detected more patients with de novo oligometastatic and multimetastatic disease and produced stage migration in intermediate- to high-risk patients. These findings reflect increased detection and reclassification, and were associated with changes in the intended treatment plan. However, because no independent reference standard or follow-up was available, they do not establish improved diagnostic accuracy.
Indexed as
Identifiers
42802268What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.